01.09.2022 - - First clinical candidate of a new class of systemically delivered conditionally activated INDUKINE therapeutics developed by Werewolf - WTX-124 is designed to target delivery of a highly potent, wild-type IL-2 cytokine to the tumor . Seite 1
Werewolf to receive $15 million upfront payment, with potential for up to $1.26 billion in development, regulatory and sales milestone payments in addition to royalties on future net
/PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Werewolf Therapeutics, Inc. (Nasdaq: HOWL) today announced that the companies have entered into a.
24.03.2022 - -Closed upsized IPO in May 2021 raising $120 million in gross proceeds- -Announced clinical trial collaboration with Merck for WTX-124 INDUKINETM program- -Reported positive preclinical data at SITC demonstrating the potential to drive targeted .
Werewolf Therapeutics to Present at Jefferies Virtual Healthcare Conference 2021 yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.